Vaccines Market Research Reports & Industry Analysis
Because of the large number of deadly diseases that have been eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements of the 20th century. Key issues in the global vaccine market today include unequal access to vaccines, supply chain disruptions, the use of vaccines to prevent pandemics and address bioterrorism, technological innovations, and vaccine hesitancy. Learn more about this critical field with the comprehensive selection of vaccine market research reports available on MarketResearch.com.
New Vaccines Market Data and Insights
- Find data on vaccine market size segmented by region, technology, distribution channel, type, route of administration, and disease.
- Gain a deep understanding of vaccine industry dynamics, market structure, growth outlook, and competitive landscape.
- Learn about influential government initiatives and new vaccination technologies that have highly promising results.
Your Source for Expert Data and Analysis
MarketResearch.com is a trusted research partner, backed by over two decades of experience. Our clients include top investment banks, management consulting firms, and leading multinational companies within the Fortune 500. Our team of research specialists is dedicated to guiding you at every step, ensuring you have the resources and insights you need to answer your toughest research questions. Browse our full list of vaccines industry reports today.
Vaccines Industry Research & Market Reports
-
Cancer Vaccines
... CAGR of 9.3% over the analysis period 2024-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$7.6 Billion by the end of the analysis ... Read More
-
Shingles Vaccines
... CAGR of 4.9% over the analysis period 2024-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$3.9 Billion by the end of the analysis ... Read More
-
Vaccine Delivery Devices
... at a CAGR of 4.4% over the analysis period 2024-2030. Syringes, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$5.3 Billion by the end of the ... Read More
-
Dengue Vaccine
... CAGR of 15.9% over the analysis period 2024-2030. Government Institutions, one of the segments analyzed in the report, is expected to record a 14.3% CAGR and reach US$774.6 Million by the end of the analysis ... Read More
-
Neoantigen Cancer Vaccines
... at a CAGR of 20.3% over the analysis period 2024-2030. Personalized Neo-Antigen Vaccine, one of the segments analyzed in the report, is expected to record a 22.3% CAGR and reach US$52.5 Million by the end ... Read More
-
Poultry Vaccines
... CAGR of 5.8% over the analysis period 2024-2030. Modified / Attenuated Live Vaccine, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$2.1 Billion by the end ... Read More
-
Typhoid Fever Vaccines
... at a CAGR of 15.7% over the analysis period 2024-2030. Live Attenuated Vaccine, one of the segments analyzed in the report, is expected to record a 16.9% CAGR and reach US$510.0 Million by the end ... Read More
-
Toxoid Vaccines
... CAGR of 3.5% over the analysis period 2024-2030. Diphtheria / Tetanus / Pertussis, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$3.7 Billion by the end ... Read More
-
Rotavirus Vaccines
... CAGR of 8.5% over the analysis period 2024-2030. Rotarix, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$6.3 Billion by the end of the analysis period. ... Read More
-
Bacterial Vaccines
... CAGR of 6.2% over the analysis period 2024-2030. Pertussis / Whooping Cough Vaccines, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$9.2 Billion by the end ... Read More
-
Polio Vaccines
... CAGR of 3.2% over the analysis period 2024-2030. Inactivated Polio Vaccine, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$624.0 Million by the end of the ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Vaccine Adjuvants
... CAGR of 9.1% over the analysis period 2024-2030. Particulate Adjuvants, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$562.7 Million by the end of the analysis ... Read More
-
Live Attenuated Vaccines
... at a CAGR of 8.9% over the analysis period 2024-2030. Bacterial vaccine, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$31.8 Billion by the end of ... Read More
-
Bacillus Calmette–Guérin (BCG) Vaccines
... 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Pediatrics, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$60.3 Million by the end ... Read More
-
Allergy Vaccines
... CAGR of 6.0% over the analysis period 2024-2030. Allergic Asthma Type, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$472.1 Million by the end of the ... Read More
-
Subunit Vaccines
... CAGR of 10.1% over the analysis period 2024-2030. Protein Antigen, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Pertussis Vaccines
... CAGR of 4.5% over the analysis period 2024-2030. DTaP Vaccine, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$5.7 Billion by the end of the analysis ... Read More
-
Nasal Vaccines
... CAGR of 7.2% over the analysis period 2024-2030. Live Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$190.5 Million by the end of the ... Read More
-
Ebola Virus Vaccines
... at a CAGR of 6.1% over the analysis period 2024-2030. cAd3-ZEBOV, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$198.9 Million by the end of the ... Read More
-
Dendritic Cell Cancer Vaccines
... 2030, growing at a CAGR of 13.0% over the analysis period 2024-2030. Sipuleucel-T Vaccines, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$987.7 Million by the ... Read More
-
Porcine Vaccines
... CAGR of 4.9% over the analysis period 2024-2030. Inactivated Vaccines Technology, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Veterinary Vaccines
... CAGR of 5.6% over the analysis period 2024-2030. Porcine Vaccines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$4.7 Billion by the end of the analysis ... Read More
-
Fish Vaccines
... CAGR of 8.0% over the analysis period 2024-2030. Killed Vaccine, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$183.0 Million by the end of the analysis ... Read More
-
Pediatric Drugs and Vaccines
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Conjugate, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$52.0 Billion by the end ... Read More
Research Assistance
